Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Requires disclosure of drug pricing and deal terms between manufacturers and insurers.
The problem
Drug prices are high and consumers don't know why. Secret deals between drug companies and insurance companies hide the true costs.
The proposal
The bill would require drug makers and insurers to publicly disclose pricing agreements, rebates, and negotiation details that are currently kept confidential.
The impact
Patients, insurers, employers, and regulators would see drug pricing information. This affects medicine costs and healthcare budgets for many Americans.
Patients and doctors would know why drugs cost what they do. This could help people make better choices about their medicine and treatment options.
Employers and insurers could compare drug prices more easily. This might create competition and push prices down over time.
Secret rebates and side agreements would be public. This could make the drug pricing system fairer for everyone.
Congress and regulators would have real data about pricing practices. This helps them make better laws about healthcare.
Drug companies say revealing deals hurts their business competition with other firms. They claim trade secrets would be exposed to competitors.
Without confidential negotiations, drug makers might set higher list prices. Transparency could reduce negotiating room for insurers.
Companies would need new systems to disclose information safely. This costs money and takes time to set up correctly.
Detailed pricing data could reveal personal insurance information. Protecting individual privacy while disclosing deals is complicated.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.